journal article·2021-12

How does biological sex affect the physiological response to nanomaterials?

Jung-Lynn Jonathan Yang, Rukhmani Narayanamurthy, Jerome Y. Yager, Larry D. Unsworth

Nano Today· Volume 41
Publisher page

Abstract

Abstract Nanomaterials are found in a wide range of industries from additives in consumer products, drug delivery vehicles, as well as environmental hazards. There is a growing body of evidence that suggests biological sex affects the host response to these nanomaterials. Given that male and female tissues do have distinct profiles of secreted factors, it is reasonable to expect that these adsorb to the surface of nanomaterials. These differences in the composition of the adsorbed biomolecular corona may induce different cellular responses based upon their biological sex. A sexual bias has been observed in the tissue-specific accumulation of nanomaterials, the extent of inflammation, and epigenetic modification induced by nanomaterials. While most of these studies involved exposure to environmental nanomaterials, there were limited examples that evaluated sexual biases related to nanomaterials for drug delivery, especially to the brain. A patient’s sex may influence the therapeutic or general host response to nanomaterials commonly used for biomedical applications. Herein, we begin with a description of the biomolecular corona as the effective interface between nanomaterials and biological systems. Then, the molecular aspects of sexual differentiation are presented regarding genetic factors, hormonal regulation, and mechanisms of processing xenobiotics, as the foundation from which to explore the sex-specific effects of nanomaterials.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticles: synthesis and applications · Reproductive System and Pregnancy · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. A.P. Arnold, X. Chen, Y. Itoh, What a Difference an X or Y Makes: Sex Chromosomes, Gene Dose, and Epigenetics in Sexual Differentiation, pp. 67–88, 2012.10.1007/978-3-642-30726-3_4 ↗
2. Sex chromosome aneuploidies
3. Gender differences in drug responses10.1016/j.phrs.2006.11.001 ↗
4. Sex differences in pharmacokinetics predict adverse drug reactions in women10.1186/s13293-020-00308-5 ↗
5. Adverse drug reactions to guideline-recommended heart failure drugs in women10.1016/j.jchf.2019.01.009 ↗
6. Sex bias in neuroscience and biomedical research10.1016/j.neubiorev.2010.07.002 ↗
7. Reporting of sex as a variable in cardiovascular studies using cultured cells: a systematic review10.1096/fj.202000122R ↗
8. Sex differences in pharmacokinetics and pharmacodynamics10.2165/00003088-200948030-00001 ↗
9. The more things change, the more they stay the same: a study to evaluate compliance with inclusion and assessment of women and minorities in randomized controlled trials10.1097/ACM.0000000000002027 ↗
10. Do you know the sex of your cells ?10.1152/ajpcell.00281.2013 ↗
11. Sex and gender analysis improves science and engineering10.1038/s41586-019-1657-6 ↗
12. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (Ranitidine) in male subjects but not females10.1007/s11095-008-9635-y ↗
13. Sex differences in the toxicity of polyethylene glycol-coated gold nanoparticles in mice
14. Sex-related responses after traumatic brain injury: consideration for preclinical modeling
15. Sex differences in brain injury and repair in newborn infants: clinical evidence and biological mechanisms10.3389/fped.2019.00211 ↗
16. Sex differences in traumatic brain injury: what we know and what we should know10.1089/neu.2018.6171 ↗
17. Sex as an important factor in nanomedicine10.1038/s41467-021-23230-9 ↗
18. The role of sex as a biological variable in the efficacy and toxicity of therapeutic nanomedicine10.1016/j.addr.2021.04.028 ↗
19. Immunological properties of engineered nanomaterials10.1038/nnano.2007.223 ↗
20. Bankruptcy of nanomedicine firm worries drug developers10.1038/533304a ↗
21. Recent advances in understanding the protein corona of nanoparticles and in the formulation of ‘stealthy ’ nanomaterials10.3389/fbioe.2020.00166 ↗
22. Understanding the lipid and protein corona formation on different sized polymeric nanoparticles10.1038/s41598-020-57943-6 ↗
23. Progress in nanomedicine: approved and investigational nanodrugs
24. The biomolecular corona of lipid nanoparticles for gene therapy10.1021/acs.bioconjchem.0c00366 ↗
25. Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity
26. Acute toxic effects and gender-related biokinetics of silver nanoparticles following an intravenous injection in mice10.1002/jat.2742 ↗
27. Renal clearance of quantum dots10.1038/nbt1340 ↗
28. Analysing the nanoparticle-protein corona for potential molecular target identification10.1016/j.jconrel.2020.03.008 ↗
29. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes10.1016/0005-2736(89)90307-6 ↗
30. Serum opsonins and liposomes - their interaction and opsonophagocytosis
31. Understanding the nanoparticle – protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles10.1073/pnas.0608582104 ↗
32. Biomolecular coronas provide the biological identity of nanosized materials10.1038/nnano.2012.207 ↗
33. Lipid-mediated targeting with membrane- wrapped nanoparticles in the presence of corona formation10.1021/acsnano.5b06501 ↗
34. A decade of the protein corona10.1021/acsnano.7b08008 ↗
35. Protein corona: a new approach for nanomedicine design10.2147/IJN.S129300 ↗
36. Regulation of macrophage recognition through the interplay of nanoparticle surface functionality and protein corona10.1021/acsnano.6b00053 ↗
37. Understanding the kinetics of protein − nanoparticle corona formation10.1021/acsnano.6b04858 ↗
38. Effect of adsorbed proteins on the wettability of hydrophilic and hydrophobic solids10.1038/196476a0 ↗
39. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts10.1073/pnas.0805135105 ↗
40. Nanomedicine delivery: does protein corona route to the target or off road?10.2217/nnm.15.163 ↗
41. Evolution of the nanoparticle corona10.1038/nnano.2017.61 ↗
42. Mapping and identification of soft corona proteins at nanoparticles and their impact on cellular association10.1038/s41467-020-18237-7 ↗
43. The nanomaterial metabolite corona determined using a quantitative metabolomics approach: a pilot study10.1002/smll.202000295 ↗
44. HMDB 4.0: the human metabolome database for 201810.1093/nar/gkx1089 ↗
45. A draft map of the human proteome10.1038/nature13302 ↗
46. Secreted biomolecules alter the biological identity and cellular interactions of nanoparticles10.1021/nn4061012 ↗
47. Conceptual frameworks and mouse models for studying sex differences in physiology and disease: why compensation changes the game10.1016/j.expneurol.2014.01.021 ↗
48. Sex differences in early embryogenesis: inter-chromosomal regulation sets the stage for sex-biased gene networks10.1002/bies.201800073 ↗
49. Sex-chromosome dosage effects on gene expression in humans10.1073/pnas.1802889115 ↗
50. The role of sex in the genomics of human complex traits10.1038/s41576-018-0083-1 ↗
51. Early sexual differentiation of diencephalic dopaminergic neurons of the rat in vitro10.1007/BF00224125 ↗
52. Sex-specific and lineage-specific alternative splicing in primates10.1101/gr.099226.109 ↗
53. Tissue-specific expression and regulation of sexually dimorphic genes in mice10.1101/gr.5217506 ↗
54. Sexual dimorphism in the age of genomics: how, when, where10.3389/fcell.2019.00186 ↗
55. Genetics of the human Y chromosome and its association with male infertility10.1186/s12958-018-0330-5 ↗
56. The biology and evolution of mammalian Y chromosomes10.1146/annurev-genet-112414-055311 ↗
57. SRY and sex determination in mammals10.1146/annurev.ge.27.120193.000443 ↗
58. The delicate balance between male and female sex determining pathways: potential for disruption of early steps in sexual development10.1111/j.1365-2605.2009.01001.x ↗
59. Xist RNA repeat E is essential for ASH2L recruitment to the inactive X and regulates histone modifications and escape gene expression10.1371/journal.pgen.1006890 ↗
60. Xist-dependent imprinted X inactivation and the early developmental consequences of its failure10.1038/nsmb.3365 ↗
61. X chromosome inactivation is initiated in human preimplantation embryos10.1016/j.ajhg.2009.05.003 ↗
62. X chromosome inactivation in human development10.1242/dev.183095 ↗
63. X-chromosome inactivation during preimplantation development and in pluripotent stem cells10.1159/000508610 ↗
64. Recent insights into the regulation of X-chromosome inactivation
65. Escape artists of the X chromosome10.1016/j.tig.2016.03.007 ↗
66. X-chromosome inactivation and escape10.1007/s12041-015-0574-1 ↗
67. Heterogeneous gene expression from the inactive X chromosome: an X-linked gene that escapes X inactivation in some human cell lines but is inactivated in others10.1073/pnas.96.13.7364 ↗
68. X-inactivation profile reveals extensive variability in X-linked gene expression in females10.1038/nature03479 ↗
69. Review X chromosome inactivation and active X upregulation in therian mammals: facts, questions, and hypotheses10.1093/jmcb/mjv001 ↗
70. Human X chromosome inactivation and reactivation: implications for cell reprogramming and disease
71. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome10.1038/349038a0 ↗
72. Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome10.1038/351329a0 ↗
73. Requirement for Xist in X chromosome inactivation10.1038/379131a0 ↗
74. Epigenetic events regulating monoallelic gene expression10.3109/10409238.2015.1064350 ↗
75. X inactivation and escape: epigenetic and structural features10.3389/fcell.2019.00219 ↗
76. Gender differences in kidney function10.1007/s00424-007-0308-1 ↗
77. Sex steroid effects at target tissues: mechanisms of action10.1152/advan.00086.2006 ↗
78. The biology of human sex differences10.1056/NEJMra052529 ↗
79. Androgen receptor structure, function and biology: from bench to bedside
80. The diversity of sex steroid action: regulation of metabolism by estrogen signaling10.1530/JOE-11-0044 ↗
81. Estrogen receptor signaling mechanisms
82. Involvement of sex hormonal regulation of K+ channels in electrophysiological and contractile functions of muscle tissues10.1016/j.jphs.2019.02.009 ↗
83. Steroid signaling activation and intracellular localization of sex steroid receptors10.1007/s12079-010-0103-1 ↗
84. Androgen effects on the adrenergic system of the vascular, airway, and cardiac myocytes and their relevance in pathological processes10.1155/2020/8849641 ↗
85. Effect of testosterone on potassium channel opening in human corporal smooth muscle cells10.1111/j.1743-6109.2007.00732.x ↗
86. The TRPM8 protein is a testosterone receptor10.1074/jbc.M114.610873 ↗
87. Sex differences in drug disposition
88. How important are gender differences in pharmacokinetics ?10.2165/00003088-200241050-00002 ↗
89. Gender-specific pathway differences in the human serum metabolome10.1007/s11306-015-0829-0 ↗
90. Metabolomics analysis of human plasma metabolites reveals the age- and sex-specific associations10.1080/10826076.2019.1701016 ↗
91. Gender differences in pharmacological response10.1016/S0074-7742(08)00001-9 ↗
92. Sex hormones and the immune response in humans10.1093/humupd/dmi008 ↗
93. Basic review of the cytochrome P450 system
94. Sex differences in drug effects: interaction with sex hormones in adult life
95. Gender aspects in cardiovascular pharmacology10.1007/s12265-009-9114-9 ↗
96. Sex-specific differences in CYP450 isoforms in humans10.1517/17425255.4.4.413 ↗
97. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation10.1016/j.pharmthera.2012.12.007 ↗
98. Size and surface modification of amorphous silica particles determine their effects on the activity of human CYP3A4 in vitro10.1186/1556-276X-9-651 ↗
99. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases10.1093/eurheartj/ehi397 ↗
100. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary neoplasms10.1016/S0022-3565(25)12089-2 ↗